Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: CETP inhibition-is it time for a revival?
Logo

American Heart Association

  77
  0

Final ID:

Discussant: CETP inhibition-is it time for a revival?

  • Watson, Karol  ( UCLA , Redondo Beach , California , United States )
    • Author Disclosures:
    KAROL WATSON: DO have relevant financial relationships ; Advisor:amgen:Active (exists now) ; Consultant:novartis:Active (exists now) ; Consultant:boehringer engelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
Don't Let Up: An Ounce of Prevention is Worth a Pound in Cardio-Oncology

Watson Karol, Lloyd-jones Donald

2025 AHA/ACC BP Guideline: The 12 Key Takeaways You Can't Miss

Watson Karol

You have to be authorized to contact abstract author. Please, Login
Not Available